Periodic Reporting for period 1 - LIBERATE (Blood Biomarker Array Technology)
Reporting period: 2015-07-01 to 2015-10-31
The GP consultation established the value chain for the GDA identifying the current costs. Our estimates for the UK suggest this process costs €184 - €244 including all of the time to organise the logistics. The GDA will free up 20M GP second appointments annually, saving the NHS €2.1bn in addition to providing the patient with the tests results and care pathway at the first meeting.
Our initial set of tests confirmed by the GPs was: CRP, White Blood Cells, D-Dimer, Troponin I/T, C3 and C4. The results for CRP were completely successful with a CV of 5.2% compared with standard laboratory measurements. Development is on going for C3 (CV 18%) and C4, Troponin T/I, D-dimer where the results were qualitative.
The feasibility study has clearly demonstrated a market for a new vision of patient care - “Test and Treat the Patient” - which includes significant benefits to both to patient outcome and health economic advantages and the additional new idea of using the patient as their baseline. If normal-for-the-patient levels are known then small changes can be detected enabling a care pathway tailored for each patient to be managed, no matter where they are geographically. Our array technology will truly LIBERATE public healthcare.
GDA Specification for the GP Practice Market (Deliverable 1)
GDA assay bill of materials and protocol; (Deliverable 2)
The Health Economic Case for GP market usage (Deliverable 3)
Prototype Process assessment to deliver the CE-marked instrument – full cost (Deliverable 4)
The conclusion of the action – The Attomarker Business Plan (Deliverable 5)